CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a...
15 KB (1,738 words) - 05:58, 17 August 2024
infusion. The medication consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins...
13 KB (1,246 words) - 02:44, 14 August 2024
patients were treated with the recombinant immunotoxin which targets the CD22 cell surface receptor on these leukemic cells. In two uncontrolled clinical...
4 KB (573 words) - 11:44, 13 August 2023
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory...
17 KB (1,438 words) - 04:13, 16 July 2024
An anti-CD22 immunotoxin is a monoclonal antibody targeting CD22 linked to a cytotoxic agent. As of August 2009, it was studied in the treatment of some...
9 KB (859 words) - 17:11, 13 September 2024
cell therapy targeting CD22 for the treatment of relapsed/refractory ALL and will be leading a trial using a combinatorial CD19/CD22 targeted CAR-T cell...
12 KB (1,200 words) - 05:35, 18 November 2024
Parallel studies by Ajit Varki and colleagues on the previously cloned CD22 (a B cell surface protein involved in adhesion and activation) showed direct...
35 KB (3,968 words) - 06:48, 16 September 2024
district RAND California Election Returns: District Definitions California Voter Foundation map - CD22 35°12′N 119°54′W / 35.2°N 119.9°W / 35.2; -119.9...
59 KB (564 words) - 23:49, 4 January 2025
larger than normal and positive for CD19, CD20, CD22, CD11c, CD25, CD103, and FMC7 antigens. (CD103, CD22, and CD11c are strongly expressed.) Annexin A1...
53 KB (6,579 words) - 17:52, 2 January 2025
monoclonal antibody, inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate, was approved by the U.S. Food and Drug...
16 KB (1,506 words) - 18:06, 10 February 2024
B-cells based on their expression of B-cell marker proteins (e.g. CD20, CD19, CD22, CD79, PAX5, BOB1, OCT2, an immunoglobulin [usually IgM but occasionally...
69 KB (8,143 words) - 23:37, 9 November 2024
endpoint. Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells. Elevated CD22 and other B-cell receptor (BCR) proteins are associated...
5 KB (377 words) - 23:53, 14 June 2023
T cell CD45+, CD3+, CD8+ B lymphocyte CD45+, CD19+, CD20+, CD24+, CD38, CD22 Thrombocyte CD45+, CD61+ Natural killer cell CD16+, CD56+, CD3-, CD31, CD30...
14 KB (1,446 words) - 16:23, 9 December 2024
other small B-cell NHLs. B-cell-associated antigens such as CD19, CD20, CD22, and CD79a are usually expressed. In contrast to small lymphocytic lymphoma...
19 KB (2,138 words) - 05:12, 30 December 2024
differentiation, cell surface proteins – namely CD30, with CD19, CD20 and CD22, and with the absence of CD15. Other markers may also be used to confirm...
43 KB (5,062 words) - 19:32, 22 December 2024
ATC code L01 Antineoplastic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes...
13 KB (935 words) - 04:36, 23 December 2024
67020 GBIF: 1237285 iNaturalist: 377629 IRMNG: 1335409 NCBI: 2877358 NZOR: b532eec5-cd22-4017-b56d-edaaf8829b87 Open Tree of Life: 4612255 WoRMS: 989807...
5 KB (422 words) - 21:58, 31 August 2024
CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36...
33 KB (3,930 words) - 03:43, 25 December 2024
CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36...
75 KB (9,082 words) - 15:56, 2 November 2024
CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36...
11 KB (1,335 words) - 22:36, 11 October 2024
CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36...
30 KB (3,464 words) - 22:51, 24 May 2024
approved (FDA) Year approved (EMA) Inotuzumab ozogamicin (Besponsa) Anti-CD22 monoclonal antibody-drug conjugate Relapsed or refractory B cell precursor...
11 KB (842 words) - 13:15, 12 February 2024
— February 6, 1997 Kitt Peak Spacewatch NYS 1.7 km MPC · JPL 73881 1997 CD22 — February 13, 1997 Oizumi T. Kobayashi NYS 1.8 km MPC · JPL 73882 1997 CZ25...
178 KB (301 words) - 17:31, 30 November 2023
Immunological markers B cell Lineage T cell Lineage B cell lineage CD19, CD22, CD79a + − CD10 − or + (common ALL) cytoplasmic Ig − or + (pre-B ALL) surface...
80 KB (7,799 words) - 16:17, 2 January 2025
express B-cell surface markers including the CD10 (60% of cases), CD20, CD19, CD22, and CD79 but not CD5, CD11c, or CD23 cell surface proteins; genomic analyses...
68 KB (8,025 words) - 06:16, 29 December 2024
as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) on June 30,...
41 KB (4,305 words) - 07:25, 14 December 2024
CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36...
12 KB (1,369 words) - 07:17, 15 October 2024
2007. The most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014...
88 KB (9,266 words) - 19:20, 2 January 2025
phospho-proteins involved in hematopoietic cell signaling, (e.g., the LYN-CD22-SHP-1 pathway). Multiple alternatively spliced variants of this gene, which...
20 KB (2,292 words) - 02:56, 28 March 2024
"dystrophic" microglia in the human brain. In mice, it has been shown that CD22 blockade restores homeostatic microglial phagocytosis in aging brains. Microglia...
49 KB (5,772 words) - 15:16, 18 December 2024